No products in the cart.
Fulzerasib Tablets (Dupert) – 150mg
$1.00
Fulzerasib (Dupert) is an orally active KRAS G12C inhibitor, conditionally approved in China for advanced non–small-cell lung cancer (NSCLC) with KRAS G12C mutation. Manufactured by CindaBio, NMPA approved under H20240035 (drug code: 86985200000015). Strictly for laboratory research use only—NOT for clinical or human consumption.
Description
Fulzerasib Tablets Product Specifications
| Attribute | Details |
|---|---|
| Product Name | Fulzerasib Tablets (Dupert) |
| Dosage & Quantity | 150mg per tablet × 112 tablets per box |
| Formulation | Film-coated tablet |
| Chinese Approval No. | NMPA H20240035 |
| Product Code | 86985200000015 |
| Manufacturer | (CindaBio) |
| Intended Use | Laboratory research only; not for human use |
Fulzerasib Tablets Overview & Mechanism
Fulzerasib is a covalent KRAS G12C inhibitor, irreversibly binding to the mutant cysteine 12 residue. It blocks KRAS-driven signaling (RAF–MEK–ERK, PI3K–AKT), inducing tumor cell growth arrest and apoptosis—and may also modulate the tumor immune microenvironment pharmaceutical-technology.com+15cancernetwork.com+15pubmed.ncbi.nlm.nih.gov+15synapse.patsnap.com.
Fulzerasib Tablets Research & Clinical Data
China Conditional Approval (Aug 2024) for KRAS G12C+ advanced NSCLC after 1 prior treatment
Phase II (NCT05005234): ORR 49.1%, DCR 90.5%, median PFS 9.7?mo; median OS not reached in 116 patients
Combination Study (KROCUS): Fulzerasib + cetuximab showed ORR ~80% and DCR ~100%, including CNS activity in brain metastases
Fulzerasib Tablets Research Applications
Perfect for:
KRAS G12C molecular studies in vitro/in vivo
NSCLC tumor biology and resistance pathways
Signal-transduction profiling and biomarker investigations
Combo therapy research (e.g., with EGFR inhibitors)
Handling & Storage
Store at room temperature (20–25?°C); avoid light and moisture.
Handle with standard lab PPE; avoid ingestion or inhalation.
Packaging: Sealed blister box—inspect integrity before use.
References
China NMPA approval (Aug 2024) firstwordpharma.com+9cancernetwork.com+9english.nmpa.gov.cn+9
Phase II trial results delveinsight.com+4jto.org+4firstwordpharma.com+4
KRAS inhibition mechanism genfleet.com+13synapse.patsnap.com+13oncpracticemanagement.com+13
Fulzerasib + cetuximab combo data cancernetwork.com+15onclive.com+15jto.org+15
1 review for Fulzerasib Tablets (Dupert) – 150mg
Related products
Propranolol Hydrochloride Oral Solution
Propranolol Hydrochloride Oral Solution (HeMeiJia) offers a sweet strawberry-mint 40mg/5mL formulation in a 40mL bottle. Approved by NMPA under H20213549, this solution provides accurate dosing—ideal for infantile hemangioma, pediatric cardiovascular, or pharmacokinetic studies.
$1.00Ivodazumab Injection (lvonescimab)
Ivodazumab (Yidafang) is a monoclonal antibody developed by Kangfang Pharmaceutical Co., Ltd., approved by China's NMPA (Approval No. S20240020; Drug Code: 86985204000011). Each vial contains 10ml of the injectable formulation. Strictly for laboratory research use only—not for clinical or human use.
$1.00Abiraterone Acetate Tablets (Hengrui) – 250mg
Abiraterone acetate is a potent CYP17A1 inhibitor used clinically to suppress androgen synthesis in prostate cancer. Manufactured by Chengdu Shengdi Pharmaceutical Co., Ltd., with China NMPA approval under H20193205 (product code: 86980435000069). This product is for laboratory research and development use only—not for clinical or therapeutic use. $2.00Elranatamab Injection
Elranatamab (ELREXFIO®) is a BCMA-CD3 bispecific antibody used in multiple myeloma research. Supplied as a 76mg/1.9mL single-dose vial, manufactured by Pfizer. Approved by FDA (Aug 2023) and EMA (Dec 2023). Ideal for oncology, immunotherapy, and Tcell engager studies.
$1.00
barras –
Thanks